However, delineating this paradigm in patients has been challenged by at least two main factors: 1) both insulin action and clearance depend on the rapid insulin binding to its receptor, and 2) in the Western world, most patients exhibit systemic insulin resistance with prominent abdominal obesity that could prohibit a fair assessment of an earlier onset of reduced insulin clearance. The gene discussed is INS; the disease is Insulin resistance.